PPIX

Light penetration depth in brain with different photosensitizers

  Motivation for the study Glioblastoma is the most aggressive and lethal brain cancer with an average prognosis of 15 months. Fluorescence-guided surgery (FGS) for glioblastoma was FDA-approved in 2017, while photodynamic therapy (PDT) remains an active area of clinical investigation with very promising results so far. The aim of PDT is to eradicate the […]

Light penetration depth in brain with different photosensitizers Read More »

ML7710 for glioblastoma treatment

Customer case Research by: University Hospital Münster provides cutting-edge medical treatments for patients all over the world. The department of neurosurgery provides a full spectrum of neurosurgical care with interdisciplinary vascular and neuro-oncological specialization. Modulight products: ML7710, ML7710i Laser use: Randomized controlled PDT trials for both newly diagnosed and recurrent glioblastoma, as well as compassionate care

ML7710 for glioblastoma treatment Read More »

Cloud-based medical laser platform for phototherapy and treatment monitoring for glioblastoma

Presented in: SPIE BIOS 2021 Authors: Zoe Ylöniemi, Visa Kaivosoja, Juha Lemmetti, Timo Tanila, Eero Koivumäki, Lasse Orsila, Petteri Uusimaa    

Cloud-based medical laser platform for phototherapy and treatment monitoring for glioblastoma Read More »

Combination of ALA-induced fluorescence-guided resection and intraoperative open photodynamic therapy for recurrent glioblastoma: case series on a promising dual strategy for local tumor control

Published in: Journal of Neurosurgery Authors: Stephanie Schipmann, Michael Müther, Louise Stögbauer, Sebastian Zimmer, Benjamin Brokinkel, Markus Holling, Oliver Grauer, Eric Suero Molina, Nils Warneke, Walter Stummer    

Combination of ALA-induced fluorescence-guided resection and intraoperative open photodynamic therapy for recurrent glioblastoma: case series on a promising dual strategy for local tumor control Read More »

Scroll to Top